SS Innovations International, Inc. annual report, FY2017

Business context and reporting period

The supplied filing is AVRA Medical Robotics, Inc.’s audited Form 10-K for the fiscal year ended December 31, 2017, filed March 29, 2018. This does not match the request metadata naming SS Innovations International, Inc.; verify the issuer before relying on this summary. AVRA was a development-stage medical robotics company developing a robotic skin-resurfacing system with the University of Central Florida (UCF). It had no products ready for marketing and had not generated revenue.

Financial performance and position

2017 basic and diluted loss per share was $0.05, versus $0.03 in 2016. No meaningful revenue margins were reported. At December 31, 2017, total assets were $509,962, current assets $463,029, current liabilities $408,869, and stockholders’ equity $101,093. Current liabilities included a $284,750 stock liability and $118,046 in accrued expenses. The $480,000 of 7.5% convertible notes outstanding at year-end 2016 converted into 960,000 common shares in 2017; no promissory notes remained at year-end 2017. Interest expense was $27,000. No income tax provision was recorded.

Changes versus prior year

Net loss more than doubled, primarily as general and administrative expense rose by $604,722, reflecting management compensation, SEC registration-related professional costs, and stock-based compensation. Research and development expense fell by $56,408, which management attributed to completion of UCF’s first research phase. Operating cash use increased, while cash rose with $677,260 of cash proceeds from common-stock offerings. The company also converted debt and accrued compensation into equity, increasing shares outstanding to 20,644,746 at year-end.

Outlook, risks and unusual items

• Management expected substantial additional capital to continue development and planned to seek securities financing and, if possible, development partnerships. No committed funding sources existed; management warned that failure to raise capital could force reduced operations and raised substantial doubt about the company’s ability to continue as a going concern. Additional financing could materially dilute shareholders.
• The prototype remained under development. FDA clearance or approval would be required, and the filing gave an estimated $200,000–$500,000 cost for the approval process and a possible six-month-to-two-year timeline. Neither timing nor approval was assured; the filing states no product was ready for retail marketing.
• The UCF research agreement was extended without additional payments, and a $68,952 matching grant was subject to research obligations; failure to meet them could cause loss of grant funding and require AVRA to cover a shortfall. The filing gives inconsistent extension end dates: June 30, 2019 in the business section and September 30, 2019 in the financial-statement note.
• Disclosure controls were reported ineffective due to material weaknesses involving internal-control documentation, evaluation and testing, and segregation of duties. Remediation depended on resources becoming available. The company had no audit committee.
• The company reported no pending or threatened legal proceedings and no material off-balance-sheet arrangements. Its common stock had no public market; plans to seek OTCQB quotation were not assured.
• Auditors issued an unqualified opinion on the financial statements. The filing disclosed $168,301 of cash above the FDIC insurance limit at year-end 2017.

Important facts for investors to verify

1. Confirm the issuer: the request identifies SS Innovations International, Inc., but the supplied 10-K is for AVRA Medical Robotics, Inc.
2. Review the complete audited statements and subsequent filings for cash burn, funding raised, accrued obligations, and developments affecting the going-concern risk.
3. Verify prototype progress, the applicable UCF agreement end date, grant compliance, FDA pathway, expected costs, and any resulting regulatory or commercialization milestones.
4. Assess the material weaknesses and whether controls were remediated, as well as the effects of stock-based compensation, conversions, and future financing on dilution.